Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor mutational burden (TMB) impacts colorectal cancer survival differently. Low TMB correlates with worse outcomes, while high TMB indicates better survival, especially in extreme cases.
Area Of Science
- Oncology
- Genomics
- Cancer Research
Background
- Colorectal cancer prognosis is complex, with extreme cases often overlooked.
- Understanding prognostic factors is crucial for personalized treatment.
Purpose Of The Study
- To investigate the role of tumor mutational burden (TMB) in colorectal cancer patient prognosis.
- To identify potential biomarkers for stratifying patients with exceptional survival outcomes.
Main Methods
- Developed an analytical framework using TMB to analyze 1277 colorectal cancer patients.
- Assessed survival variations across a wide spectrum of TMB levels in patients not receiving immunotherapy.
Main Results
- Patients with TMB ≤ 10 mutations per megabase (mut/Mb) showed worse survival as TMB increased.
- Patients with TMB > 10 mut/Mb demonstrated improved survival with increasing TMB.
- A subgroup with TMB > 60 mut/Mb exhibited significantly better survival.
Conclusions
- TMB plays a dual role in colorectal cancer progression and survival.
- TMB can identify patients with exceptionally good or poor prognoses.
- TMB serves as a valuable biomarker for predicting outcomes and personalizing treatment in colorectal cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
